Video modal
popup modal
The MHICC is now Seriant !
The Montreal Health Innovations Coordinating Center (MHICC) is now Seriant.
Our new name reflects a bold step forward— expanding beyond cardiology and embracing innovations in clinical trials with a global reach.
While our identity has evolved, our commitment to operational excellence, client satisfaction, and quality remains the same.
Seriant Continues Partnership with COSCIENS Biopharma Inc. to Advance Avenanthramides into Phase 2a Clinical Trial
March 13, 2025
Montréal, QC — March 13, 2025 — Seriant, a leading Clinical Research Organization (CRO), announced today its collaboration with COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) to support the advancement of Avenanthramides, an investigational anti-inflammatory product, from Phase 1 to Phase 2a. This partnership builds on the successful completion of the Phase 1 portion of COSCIENS’ AvenActive study, which demonstrated an excellent safety profile with no significant adverse events.
The Phase 2a clinical trial underway at the Montreal Heart Institute will assess the potential efficacy of Avenanthramides in patients with mild to moderate inflammation. Seriant will provide comprehensive clinical research services, leveraging its expertise to ensure seamless execution of this critical phase.
Sophie Tanguay, Executive Director of Seriant (formerly MHICC), stated: “We are proud to continue our partnership with COSCIENS Biopharma in advancing the clinical development of Avenanthramides. This collaboration highlights our commitment to supporting innovative therapies that have the potential to address unmet medical needs. Together, we are taking a significant step toward exploring new treatment options for patients living with chronic inflammatory conditions.”
Avenanthramides are di-phenolic compounds derived exclusively from oats and have shown promising antioxidant and anti-inflammatory properties in preclinical studies. The findings from this trial could provide critical insights into their role in managing inflammation-driven conditions.
About COSCIENS Biopharma Inc.
COSCIENS Biopharma Inc. (NASDAQ: CSCI) is a life sciences company focused on developing cosmeceutical, nutraceutical, and pharmaceutical products derived from natural plant-based resources. The company is dedicated to advancing treatments for inflammation-related conditions and other chronic diseases through its innovative portfolio of therapies. For more information, please visit COSCIENS' website at www.cosciensbio.com.
About Seriant:
Seriant is a Montreal-based full-service Clinical Research Organization (CRO) with global reach. We specialize in supporting pharmaceutical, biotechnology, and medical device companies in their Phase 1 to 4 clinical studies. Our team of experts partners with industry leaders to ensure efficient and compliant execution of clinical trials aimed at improving patient outcomes.
For more information, visit www.seriant.org
https://www.linkedin.com/company/seriant
